After Posting Net Loss in Q4, SQI Diagnostics Pins Hopes on Service Business | GenomeWeb

By Justin Petrone

The year 2011 was eventful for Toronto-based microarray firm SQI Diagnostics: While the company managed to get several of its assays cleared for clinical use by regulatory authorities in the US and Canada, market conditions also forced it to abandon its bid to go public in the US and terminate its acquisition of German array company Scienion.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.